Next Phase Newsletter

A UK based venture capital firm is looking to invests in early-stage, high-growth life science and health technology companies. The firm (2013 vintage year) primarily provides Series A financing in the range of £2-5M. The firm is actively seeking new investment opportunities in the UK and Europe.

The firm is currently seeking to invest in novel early stage biotech therapeutic and diagnostic, medical devices and pharmaceuticals. The firm is opportunistic in terms of subsectors and indications. The firm is also interested in other areas such as personalized medicine, healthcare IT and services. For therapeutics, the firm focuses on products in pre-clinical and early clinical and will consider orphan indications.

The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm that firm manages approximately $500 million under management and is currently investing out of its 2014 vintage $200 fund. The firm looks to make investments of $5-$15 million initially up to $20 million over the investments lifetime. The firm is willing to invest throughout the United States and is looking to make approximately 4-6 equity investments over the next 6 to 9 months.

The firm is currently interested in companies in the Medical Device, Healthcare IT and Healthcare Services Sectors. In the Medical Devices space the firm is currently looking for companies shipping technologies that advance minimally invasive procedures in the fields of cardiology, urology, oncology, gynecology, orthopedics, neurosurgery and general surgery. The firm also looks for high-potential devices that serve an aging population that is seeking to stay active longer. Another area of interest is companies that are developing diagnostic technologies for personalized medicine.

The firm is looking for companies with revenues of at least $1-$2 million and the firm’s ideal candidates have revenues in the range of $3-$15 million. The firm has stated that they will gladly speak with medical device companies that may be outside of their investment scope in order to build relationships for the future.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture capital fund of a large Russian conglomerate with additional representation in New York, Zurich, and the UK id exclusively focused on early stage life science companies. The fund can invest up to USD 5 million per company generally in seed and series A rounds. The firm is open to investing globally and is actively seeking new investment opportunities. 

The fund is primarily focused on early-stage therapeutics, diagnostics, and medical devices. However, the firm may consider health IT. For therapeutics, the firm is agnostic in terms of subsectors and indications however only looking for products in pre-clinical to early-clinical is. The firm is also agnostic in terms of subsector and indication for diagnostics and medical devices but again is only interested in the early stage.

The fund seeks a strong and entrepreneurial management team and seek a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global beauty and health company is looking to invest in in early and later stage opportunities which are strategically relevant to and complement the firm’s current product lines. The firm’s investment size is USD 2-5 million per company per round with reserved follow-on investments. The firm can invest globally and is actively seeking new investment opportunities.

In the Life Sciences, the firm seeks to invest in emerging companies that develops novel cosmetic therapeutics and related medical devices. The firm’s investment focuses include dermatology therapeutics targeting, acne, stretch marks, rosacea, psoriasis, anti-fungal, as well as post-surgical treatment such as wound healing and scars. Other areas of interest include technology enhancing topical ingredient delivery, novel formulation technologies, emerging biotechnologies such as stem cells, gene profiling for cosmetic indications are also of interest.

On a case by case basis the firm can act as lead investor or participate in a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture arm of European chemical company invests in companies developing technologies that are of strategic interest. The fund is flexible regarding investment and partnerships; most investments are made in Series A rounds but both seed-stage opportunities and later-stage opportunities may be of interest. Initial investments typically range from $1-7 million, and the fund generally syndicates with other investors. The fund will consider opportunities globally. In addition to capital the fund is able to provide strategic guidance and technical expertise to its portfolio companies.

Within the life science sector, the fund is interested in excipients, custom manufacturing and formulation, medical device coatings, agrochemicals, plant biotech (particularly technology that increases crop yield such as GMOs), industrial biotech (including fermentation), and medical uses of nanotechnology (including nanotech mechanisms for drug delivery). Within the coatings subsector, the fund is particularly interested in coatings that can be applied to polymers/surface technologies developed by the funds parent company.

The fund generally invests in pre-revenue companies that have developed proof of concept data or a prototype, and which have filed for patents. The fund always request a board seat subsequent to investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was founded in 2011 and is based in China is managing one fund with committed capital of $140million. The firm typically makes equity investment into life science companies at various stages. The investment size generally ranges from $10 million to $15 million over the life of an investment. The firm seeks to make 3-5 allocations in the next year. The firm focuses on companies that are based in the China and the US.

The firm is currently looking for new investment opportunities in Biotechnology R&D, Therapeutics & Diagnostics, Pharmaceuticals, Medical Devices and Healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-license products or technologies for development from companies outside of China, such as US-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture investment and development firm based in the Southern United Sates provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $500K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic and is actively seeking new opportunities. 

The firm is currently looking for medical device companies/start-ups developing products with a 510(k) regulatory pathway. The firm primarily focuses on Class II medical devices but will also consider Class III. Preferably, the product should have a prototype and animal data. The firm is open to all target markets, but is more interested in cardiovascular, interventional cardiology, interventional radiology, cardiac surgery, vascular surgery, critical care, consumable product, patient care, and orthopedic markets.

The firm takes an active role in the management of portfolio companies. The firm seeks Board representation and participation as Executive Management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com